Celladon Corp., a La Jolla, CA-based developer of treatments for cardiovascular diseases, has closed a $43m in funding.
The round was led by Pfizer Venture Investments, with participation from Lundbeckfond Ventures, Novartis Venture Funds, H&Q Healthcare/Life Sciences Investors, and GBS Venture Partners, as well as existing investors Enterprise Partners Venture Capital, Johnson & Johnson Development Corporation and Venrock Associates.
The company intends to use the capital to advance its lead investigational product candidate MYDICAR® for the treatment of heart failure. Celladon’s lead development program is designed to treat congestive heart failure by using a recombinant adeno-associated viral (AAV) vector to restore production of an enzyme that regulates calcium cycling and contractility in heart muscle cells.
In conjunction with this financing, the company has added new directors to its board:
- Barbara Dalton, Ph.D., of Pfizer Venture Investments (Chair),
- Johan Kordel, Ph.D., Assoc. Prof., of Lundbeckfond Ventures,
- Lauren Silverman, Ph.D., of Novartis Venture Funds,
- Daniel Omstead, Ph.D., of Hambrecht & Quist Capital Management, and
- Josh Funder, D.Phil., of GBS Venture Partners.
Andrew Senyei, M.D., of Enterprise Partners Venture Capital will continue to serve as a director.
Celladon plans to advance the clinical development of MYDICAR, which was granted Fast Track Status by the Food and Drug Administration in December, 2011, during the current year.